Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

References

• NguyenKDevidasMChengSCChildren’s Oncology GroupFactors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group studyLeukemia200822122142215018818707
   PubMed Web of Science ®Google Scholar
• BorowitzMJDevidasMHungerSPChildren’s Oncology GroupClinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group studyBlood2008111125477548518388178
   PubMed Web of Science ®Google Scholar
• NIH National Cancer InstituteLate Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version Available from: https://www.cancer.gov/types/childhood-cancers/late-effects-hp-pdqAccessed April 2, 2018
   Google Scholar
• GökbugetNHoelzerDTreatment of adult acute lymphoblastic leukemiaHematology Am Soc Hematol Educ Program200613314117124052
   PubMedGoogle Scholar
• HallekMChronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatmentAm J Hematol201792994696528782884
   PubMed Web of Science ®Google Scholar
• ArmitageJOHow I treat patients with diffuse large B-cell lymphomaBlood20071101293617360935
   PubMed Web of Science ®Google Scholar
• LeeDWBarrettDMMackallCOrentasRGruppSAThe future is now: chimeric antigen receptors as new targeted therapies for childhood cancerClin Cancer Res201218102780279022589486
   PubMed Web of Science ®Google Scholar
• OrentasRJYangJJWenXWeiJSMackallCLKhanJIdentification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancersFront Oncol2012219423251904
   PubMedGoogle Scholar
• LeeDWGardnerRPorterDLCurrent concepts in the diagnosis and management of cytokine release syndromeBlood2014124218819524876563
   PubMed Web of Science ®Google Scholar
• TeacheyDTLaceySFShawPAIdentification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discov20166666467927076371
   PubMed Web of Science ®Google Scholar
• SuntharalingamGPerryMRWardSCytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412N Engl J Med2006355101018102816908486
   PubMed Web of Science ®Google Scholar
• TurtleCJHanafiLABergerCImmunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cellsSci Transl Med20168355355ra116
   PubMed Web of Science ®Google Scholar
• TurtleCJHanafiLABergerCCD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJ Clin Invest201612662123213827111235
   PubMed Web of Science ®Google Scholar
• LeeDWKochenderferJNStetler-StevensonMT cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialLancet2015385996751752825319501
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar
• SchusterSJSvobodaJChongEAChimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasN Engl J Med2017377262545255429226764
   PubMed Web of Science ®Google Scholar
• ParkJHRivièreIGonenMLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaN Engl J Med2018378544945929385376
   PubMed Web of Science ®Google Scholar
• KochenderferJNDudleyMEKassimSHChemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptorJ Clin Oncol201533654054925154820
   PubMed Web of Science ®Google Scholar
• GruppSAKalosMBarrettDChimeric antigen receptor-modified T cells for acute lymphoid leukemiaN Engl J Med2013368161509151823527958
   PubMed Web of Science ®Google Scholar
• BrentjensRJDavilaMLRiviereICD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaSci Transl Med20135177177ra38
   PubMed Web of Science ®Google Scholar
• FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. United States Food and Drug Administration Press ReleaseAccessed August 30, 2017
   Google Scholar
• FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm. United States Food and Drug Administration Press ReleaseAccessed October 18, 2017
   Google Scholar
• FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm. United States Food and Drug Administration Press ReleaseAccessed May 1, 2018
   Google Scholar
• FDA approval brings first gene therapy to the United States Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm574058.htm. United States Food and Drug Administration Press ReleaseAccessed August 30, 2017
   Google Scholar
• US Department of Health and Human ServicesCommon Terminology Criteria for Adverse Events (CTCAE). V4.032010National Institutes of HealthBethesda, MD Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed March 21, 2018
   Google Scholar
• DavilaMLRiviereIWangXEfficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaSci Transl Med20146224224ra25
   PubMed Web of Science ®Google Scholar
• PorterDFreyNWoodPAWengYGruppSAGrading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucelJ Hematol Oncol20181113529499750
   PubMed Web of Science ®Google Scholar
• NeelapuSSTummalaSKebriaeiPChimeric antigen receptor T-cell therapy – assessment and management of toxicitiesNat Rev Clin Oncol2018151476228925994
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesCommon Terminology Criteria for Adverse Events (CTCAE). V5.02018National Institutes of HealthBethesda, MD Available from: https://ctep.cancer.gov/pro-tocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdfAccessed on March 09, 2018
   Google Scholar
• LeeDWSantomassoBDLockeFLASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector CellsBiol Blood Marrow Transplant Epub20181225
   Web of Science ®Google Scholar
• GustJHayKAHanafiLAEndothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discov20177121404141929025771
   PubMed Web of Science ®Google Scholar
• NorelliMCamisaBBarbieraGMonocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNat Med201824673974829808007
   PubMed Web of Science ®Google Scholar
• GiavridisTvan der StegenSJCEyquemJHamiehMPiersigilliASadelainMCAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockadeNat Med201824673173829808005
   PubMed Web of Science ®Google Scholar
• TaraseviciuteATkachevVPonceRChimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman PrimatesCancer Discov20188675076329563103
   PubMed Web of Science ®Google Scholar
• JinZXiangRQingKThe severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic reviewAnn Hematol Epub2018515
   Web of Science ®Google Scholar
• GardnerRAFinneyOAnnesleyCIntent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood2017129253322333128408462
   PubMed Web of Science ®Google Scholar
• LeeDWWayneASChimeric antigen receptor (CAR) T cellsAsciertoPAStroncekDFWangEDevelopments in T Cell Based Cancer ImmunotherapiesSwitzerlandSpringer2015
   Google Scholar
• Rose-JohnSIL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6Int J Biol Sci2012891237124723136552
   PubMed Web of Science ®Google Scholar
• BrudnoJNKochenderferJNToxicities of chimeric antigen receptor T cells: recognition and managementBlood2016127263321333027207799
   PubMed Web of Science ®Google Scholar
• MaudeSBarrettDTeacheyDTGruppSAManaging Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesCancer J201420211912224667956
   PubMed Web of Science ®Google Scholar
• LambYNDeeksEDSarilumab: a review in moderate to severe rheumatoid arthritisDrugs201878992994029931592
   PubMed Web of Science ®Google Scholar
• MaudeSLTeacheyDTPorterDLGruppSACD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaBlood2015125264017402325999455
   PubMed Web of Science ®Google Scholar
• MuellerKTWaldronERGruppSAClinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemiaClin Cancer Res Epub201896
   Web of Science ®Google Scholar
• NellanAMcCullyCMLCruz GarciaRImproved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaquesBlood2018132666266629954750
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov Identifier NCT00281294A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects with Active Rheumatoid ArthritisBethesda (MD)National Library of Medicine (US)2000 Available from: https://www.clinicaltrials.gov/ct2/show/NCT00281294?term=NCT00281294&rank=1Accessed Jan 24, 2006
   Google Scholar
• ReinischWde VilliersWBeneLFontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyInflamm Bowel Dis201016223324219637334
   PubMed Web of Science ®Google Scholar